Open access · OA
via OpenAlex
Dysregulation of the mTOR pathway in p53-deficient mice
Olga V. Leontieva, Liliya R. Novototskaya, Geraldine Paszkiewicz, Elena A Komarova, Andrei V. Gudkov, Mikhail V. Blagosklonny
Cancer Biology & Therapy · 2013 · ▲ 30 citations
Abstract
Mammalian or mechanistic target of mTOR(definition)-inhibiting drug studied for extending healthspan and lifespan." style="text-decoration:underline dotted; text-underline-offset:2px; cursor:help;">rapamycin(definition) (mTOR) is involved in growth, aging, and age-related diseases including cancer. There is an extensive cross talk between p53 and mTOR. In cell culture, p53 inhibits the mTOR pathway in a cell type-dependent manner. p53-deficient mice develop pro-inflammation and cancer. We have shown that rapamycin delayed cancer and extended lifespan, thus partially substituting for p53. Here we show that a marker of mTOR activity, phosphorylated S6 (p-S6), is increased in the hearts of p53-deficient mice. Furthermore, cardiac p-S6 correlated with body weight. Also, p53(-/-) mice were slightly hyperinsulinemic with a tendency to elevated IGF-1. Radiation exacerbated the difference between IGF-1 levels in normal and p53(-/-) mice. Noteworthy, radiation induced Thr-308 Akt phosphorylation in the livers (but not in the hearts) of both p53(+/+) and p53(-/-) mice. Simultaneously, radiation decreased p-S6 in the livers of normal mice, consistent with the negative effect of p53 on mTOR. Our data indicate that the activity of mTOR is increased in some but not all tissues of p53(-/-) mice, associated with the tendency to increased insulin and IGF-1 levels. Therefore, the absence of p53 may create oncophilic microenvironment, favoring cancer.
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- OpenAlex
- DOI
- 10.4161/cbt.26947
- Canonical
- link ↗
- Fetched
- 2026-11-07 MST
Cite this
APA
Leontieva, O.V., Novototskaya, L.R., Paszkiewicz, G., Komarova, E.A., Gudkov, A.V., & Blagosklonny, M.V. (2013). Dysregulation of the mTOR pathway in p53-deficient mice. <em>Cancer Biology & Therapy</em>. https://doi.org/10.4161/cbt.26947
Vancouver
Leontieva OV, Novototskaya LR, Paszkiewicz G, Komarova EA, Gudkov AV, Blagosklonny MV. Dysregulation of the mTOR pathway in p53-deficient mice. Cancer Biology & Therapy. 2013. doi:10.4161/cbt.26947.
BibTeX
@article{olga2013Dysreg,
title = {Dysregulation of the mTOR pathway in p53-deficient mice},
author = {Olga V. Leontieva and Liliya R. Novototskaya and Geraldine Paszkiewicz and Elena A Komarova and Andrei V. Gudkov and Mikhail V. Blagosklonny},
journal = {Cancer Biology & Therapy},
year = {2013},
doi = {10.4161/cbt.26947},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
Clinical Cancer Research 2009
Open access · OA
Deregulated GSK3 Sustains Gastrointestinal Cancer Cells Survival by Modulating Human Telomerase Reverse Transcriptase and Telomerase
Aging 2012
Open access · CC-BY
Rapamycin extends lifespan and delays tumorigenesis in heterozygous p53+/− mice
British Journal of Cancer 1997
Open access · OA
Telomerase activity in normal and malignant mammalian tissues: feasibility of telomerase as a target for cancer chemotherapy
Journal of Cellular and Molecular Medicine 2018
Open access · CC-BY
Mammalian target of rapamycin inhibition attenuates myocardial ischaemia–reperfusion injury in hypertrophic heart
bioRxiv (Cold Spring Harbor Laboratory) 2022
Preprint · CC-BY
Tissue-Restricted Inhibition of mTOR Using Chemical Genetics
Neoplasia 2001
Open access · CC-BY